Opioid and cocaine combined effect on cocaine-induced changes in HPA and HPG axes hormones in men.
Nalbuphine, a mixed micro-/kappa-opioid analgesic, may have potential as a new medication for the treatment of cocaine abuse. Kappa-opioid agonists functionally antagonize some abuse-related and locomotor effects of cocaine, and both kappa-selective and mixed micro-/kappa-opioids reduce cocaine self-administration by rhesus monkeys. Because cocaine's interactions with the hypothalamic-pituitary-adrenal and (HPA) hypothalamic-pituitary-gonadal (HPG) axes may contribute to its reinforcing properties, we examined the effects of cocaine alone and in combination with nalbuphine. Neuroendocrine effects of a single dose of cocaine alone (0.2 mg/kg, IV), with nalbuphine (5 mg/70 kg, IV)+cocaine (0.2 mg/kg, IV) in combination were compared in seven adult men (ages 18-35) who met DSM-IV criteria for current cocaine abuse. Cocaine alone, and in combination with nalbuphine was administered on separate test days under placebo-controlled, double blind conditions. Cocaine stimulated ACTH, cortisol, and LH, whereas cocaine+nalbuphine in combination produced a smaller increase in ACTH, and decreased cortisol and LH. Thus it appears that nalbuphine attenuated cocaine's effects on ACTH, cortisol, and LH. These data are consistent with our earlier report that nalbuphine modestly attenuated cocaine's positive subjective effects, and that the subjective and cardiovascular effects of cocaine+nalbuphine in combination were not additive.
Alcohol and Drug Abuse Research Center, Harvard Medical School and McLean Hospital, Belmont, MA 02478, USA. ngoletiani@mclean.harvard.edu
Nathalie V
NV
Goletiani
Jack H
JH
Mendelson
Michelle B
MB
Sholar
Arthur J
AJ
Siegel
Nancy K
NK
Mello
D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D000701:Analgesics, Opioid / Q000493:pharmacokinetics / Q000494:pharmacology*; D003042:Cocaine / Q000493:pharmacokinetics / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004347:Drug Interactions; D012739:Gonadal Steroid Hormones / Q000097:blood; D006066:Gonads / Q000187:drug effects*; D006728:Hormones / Q000097:blood*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009266:Nalbuphine / Q000493:pharmacokinetics / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology; D013739:Testosterone / Q000097:blood; D055815:Young Adult
D000701:Analgesics, Opioid; D012739:Gonadal Steroid Hormones; D006728:Hormones; D009292:Narcotic Antagonists; D013739:Testosterone; D000324:Adrenocorticotropic Hormone; D007986:Luteinizing Hormone; D003042:Cocaine; D009266:Nalbuphine; D006854:Hydrocortisone